1. Age 55-70 years

2. BMI ≥ 30 kg/m² or ≥ 27 kg/m² if also with ≥ 1 weight-related comorbidity

3. If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for ≥12 weeks prior to entry and no plans to dose escalate for the study duration

4. Willing and able to provide written informed consent and undergo all required study procedures

1. BMI >35 kg/m²

2. Uncontrolled or end-stage, comorbid, cardiometabolic disease, in the opinion of the site investigator

3. Significant neurocognitive impairment, in the opinion of the site investigator

4. Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period (see prohibited medications, section 6.0)

5. Use of insulin

6. Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period

7. Active eating disorder

8. Use of human growth hormone, tesamorelin, supraphysiologic testosterone or estradiol (stable doses for contraception, hypogonadism or other indications for exogenous sex steroid replacement therapy permitted) or anabolic steroids <12 W prior to entry, unless on a stable dose for >24 W prior to entry, or plans to start any of these medications while on study

9. Active, severe delayed gastric emptying

10. Prior bariatric surgery or major gastric surgery or plans for weight reduction surgery while on study

11. Known diabetic retinopathy

12. Personal or first-degree relative history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

13. Untreated, poorly controlled or previously undiagnosed thyroid disease

14. History of chronic pancreatitis

15. History of suicidal attempts or active suicidal ideation, in the opinion of the site investigator

16. Known allergy/sensitivity to GLP-1RA or GIPRA

17. Use or planned use of any immunomodulatory therapy or investigational therapy during the study period or use of an investigational therapy within 30 days of entry

18. Any other medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation.

19. Pregnancy, nursing or plans for either during the study period